产品封面图
文献支持

Clopidogrel hydrogen sulfate

收藏
  • ¥109 - 385
  • AmBeed已认证
  • A749538
  • 2026年06月11日
    avatar
    品牌商
    1钻石会员
  • 企业认证

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 英文名

      Methyl (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate sulfate

    • 供应商

      上海安毕达生物科技有限公司

    • CAS号

      120202-66-6

    • 规格

      50μL/1mL/25mg/50mg/100mg

    规格:50μL产品价格:¥109.0
    规格:1mL产品价格:¥385.0
    规格:25mg产品价格:¥148.0
    规格:50mg产品价格:¥247.0
    规格:100mg产品价格:¥315.0
    Clopidogrel hydrogen sulfate是一种通过抑制CYP2B6和CYP2C19防止血栓形成的抗血小板药物,IC50分别为18.2 nM和524 nM。它是一种高效的抗血栓药物,抑制ADP诱导的血小板聚集,也是口服活性的P2Y(12)抑制剂。

    Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots. Clopidogrel abolishes the inhibitory P2Y(AC) receptor-mediated ADP effects on prostaglandin E(1)-stimulated, cAMP-dependent phosphorylation of VASP (vasodilator-stimulated phosphoprotein) without affecting epinephrine, thrombin, and thromboxane signaling3. The inhibitory effect of clopidogrel on platelet consumption by the growing thrombi resulted apparently in higher platelet concentration at the collagen surface, which enhanced the platelet-collagen adhesion at all three shear rates4. Clopidogrel therapy resulted in a significant reduction in soluble CD40 ligand (P = 0.03), a prothrombotic and proinflammatory molecule derived mainly from activated platelets5. Clopidogrel (clopi) is a prodrug widely prescribed in the management of coronary artery disease and requires the intervention of hepatic cytochrome P450 2C19 (CYP2C19) for its activation6. Resistance to clopidogrel is largely a result of CYP2C19 enzyme loss of function alleles. One-year patency rates following lower extremity arterial endovascular interventions in patients with clopidogrel resistance (HPR) range between 35%-83% whereas those with the proper response to clopidogrel range between 73%-100%7.

    溶解方案(细胞实验)

    DMSO 中的溶解度 : ≥ 46.7 mg/mL (111.22 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)|H2O 中的溶解度 : 16.67 mg/mL (39.70 mM; 超声助溶)|* "≥" means soluble, but saturation unknown.

    溶解方案(动物实验)

    "方案 一": "请依序添加每种溶剂:10% DMSO 90% (20% SBE-β-CD in Saline)Solubility: ≥ 2.08 mg/mL (4.95 mM); 澄清溶液 此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液。以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。"

    "方案 二": "请依序添加每种溶剂:10% DMSO 90% Corn OilSolubility: ≥ 2.08 mg/mL (4.95 mM); 澄清溶液 此方案可获得 ≥ 2.08 mg/mL(饱和度未知)的澄清溶液,此方案实验周期在半个月以上的动物实验酌情使用。以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。"

    "方案 一": "请依序添加每种溶剂:PBSSolubility: 50 mg/mL (119.08 mM); 澄清溶液; 超声助溶"

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献
    Luo JC, Huo TI, et al. Clopidogrel delays gastric ulcer healing in rats. Eur J Pharmacol. 2012 Nov 15;695(1-3):112-9.

    Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol. 2010 Jan;105(1):34-41.

    Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):2007-11

    Roald HE, Barstad RM, Kierulf P, Skjørten F, Dickinson JP, Kieffer G, Sakariassen KS. Clopidogrel--a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost. 1994 May;71(5):655-62

    Ramadan R, Dhawan SS, Syed H, Pohlel FK, Binongo JN, Ghazzal ZB, Quyyumi AA. Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. J Cardiovasc Pharmacol. 2014 Apr;63(4):369-74

    Charfi R, Mzoughi K, Boughalleb M, Hosni H, Kouidhi S, Sfar I, Hammami N, Zaïri I, Limam M, Zedini C, Mrabet A, Klouz A, Gorgi Y, Kharrat M, Baccar H, Trabelsi S. Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism. Tunis Med. 2018 Mar;96(3):209-218

    Markel KM, Avgerinos ED. Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions. Curr Pharm Des. 2018;24(38):4554-4557

    相关实验
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥148
    TargetMol中国
    2025年07月16日询价
    ¥385
    上海优宁维生物科技股份有限公司
    2025年08月28日询价
    ¥120
    山东思科捷生物技术有限公司
    2026年06月02日询价
    ¥220
    上海嵘崴达实业有限公司
    2026年05月21日询价
    ¥5240
    西宝生物科技(上海)股份有限公司
    2025年09月09日询价
    文献支持
    Clopidogrel hydrogen sulfate
    ¥109 - 385